Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial (2001)

Peer-Reviewed Study · Sara L. Kenyon; David J. Taylor; William Tarnow-Mordi; ORACLE Collaborative Group · March 31, 2001

Sara L. Kenyon et al., 2001-03-31: ORACLE I: a multicentre randomised trial of 4,826 women with preterm prelabour rupture of membranes, testing erythromycin and/or co-amoxiclav against placebo for neonatal outcomes. It is an obstetric antibiotic trial, not a cancer trial.

Among the 2260 singletons in this comparison, significantly fewer had the composite primary outcome in the erythromycin group (125 of 1111 [11.2%] vs 166 of 1149 [14.4%], p=0.02).

Findings (journal p. 979)

Sara L. Kenyon et al., 2001-03-31: ORACLE I: a multicentre randomised trial of 4,826 women with preterm prelabour rupture of membranes, testing erythromycin and/or co-amoxiclav against placebo for neonatal outcomes. It is an obstetric antibiotic trial, not a cancer trial. This is what an 'ORACLE' trial actually is. No colorectal or adjuvant-chemotherapy ORACLE trial was found in PubMed, ClinicalTrials.gov or general search in this run. Comparator: placebo. Other ORACLE trials located: ORACLE II (CHC-24), the MRC ORACLE Children Study follow-up, ORACLE-MS (oral cladribine in multiple sclerosis, Lancet Neurol 2014) and ORACLE (oral penicillin challenge in critical care, 2024). Study type: randomized trial.